Edit Symbol List
Enter up to 25 symbols separated by commas or spaces in the text box below. These symbols will be available during your session for use on applicable pages.
Don't know the stock symbol? Use the
Symbol Lookup tool.
Alphabetize the sort order of my symbols
Investing just got easier…
Sign up now to become a NASDAQ.com member and begin receiving instant notifications when key events occur that affect the stocks you follow.Access Now X
ETFs with VRTX as a Top 10 Holding*
|Weighting||ETF Name (Symbol)||100-Day Price Change (%)|
|5.1%||PowerShares Dynamic Biotech &Genome (PBE)||+6.11 (12.46%)|
|4.39%||Market Vectors Biotech ETF (BBH)||+14.47 (12.57%)|
|3.77%||iShares Nasdaq Biotechnology Index Fund (IBB)||+50.09 (17.08%)|
|3.01%||First Trust Amex Biotech Index Fund (FBT)||+19.54 (19.80%)|
|1.99%||PowerShares DWA Healthcare Momentum Portfolio (PTH)||+8.40 (16.09%)|
Company Description (as filed with the SEC)
We are in the business of discovering, developing, manufacturing and commercializing small molecule drugs. We use precision medicine approaches to create transformative drugs for patients with serious diseases in specialty markets. Our business is focused on developing and commercializing therapies for the treatment of cystic fibrosis, or CF, and advancing our research and early-stage development programs, while maintaining our financial strength. Cystic Fibrosis Our goal is twofold: to develop treatment regimens that will provide benefits to as many patients with CF as possible and to enhance those benefits. KALYDECO KALYDECO (ivacaftor) was approved in 2012 in the United States and European Union as a treatment for patients with CF six years of age and older who have the G551D mutation in their cystic fibrosis transmembrane conductance regulator, or CFTR, gene. ... More ...
Where does VRTX fit in the risk graph?
|Annual EPS Est:||$-2.93|
|Quarterly EPS Est:||-0.82|